Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic · Oral solution

Abacavir 20 mg/mL oral solution price what pharmacies pay, and what you should

There is no weekly pharmacy acquisition cost for abacavir 20 mg/ml oral solution this week. The makers, package codes, recalls and label are below.

What did you pay for abacavir 20 mg/ml oral solution? Share it.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Supply status: shortages & recalls

No shortage reportedChecked Nov 18, 2026
No ongoing recalls1 recall on record, latest Jul 18, 2012

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

Every manufacturer and package code

3 companies sell abacavir 20 mg/ml oral solution under 3 package codes (NDCs).

All 3 package codes

A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.

Other abacavir strengths and forms

Strength and formPer unitPharmacies pay4 weeks52 weeks
300 mg tablet$0.5523$16.57 / 30 tablets+1.2%-14.4%

Official label & what changed

Last changedMarch 18, 2026
Version6 of 6
EffectiveMar 5, 2026
Read the label

These highlights do not include all the information needed to use ABACAVIR TABLETS safely and effectively. See full prescribing information for ABACAVIR TABLETS. ABACAVIR tablets, for oral use Initial U.S. Approval: 1998

This drug has a boxed warning

WARNING: HYPERSENSITIVITY REACTIONS

Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir.

Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele [see Warnings and Precautions (5.1)].

Abacavir is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients [see Contraindications (4), Warnings and Precautions (5.1)]. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir or reinitiation of therapy with abacavir, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible [see Contraindications (4), Warnings and Precautions (5.1)].

Following a hypersensitivity reaction to abacavir, NEVER restart abacavir or any other abacavir-containing product because more severe symptoms, including death can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity [see Warnings and Precautions (5.1)].

WARNING: HYPERSENSITIVITY REACTIONS

See full prescribing information for complete boxed warning.

•

Serious and sometimes fatal hypersensitivity reactions have occurred with abacavir. (5.1)

•

Hypersensitivity to abacavir is a multi-organ clinical syndrome. (5.1)

•

Patients who carry the HLA-B*5701 allele are at a higher risk of experiencing a hypersensitivity reaction to abacavir. (5.1)

•

Abacavir is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. (4)

•

Discontinue abacavir as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue abacavir if hypersensitivity cannot be ruled out, even when other diagnoses are possible. (5.1)

•

Following a hypersensitivity reaction to abacavir, NEVER restart abacavir or any other abacavir-containing product. (5.1)

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Questions about abacavir 20 mg/ml oral solution

Who makes abacavir 20 mg/ml oral solution?

3 companies: Aurobindo Pharma Limited, Camber Pharmaceuticals, Inc., Rising Pharma Holdings, Inc.. See every package code.

Is abacavir in shortage?

No shortage is reported right now. We check every day.

Has abacavir been recalled?

1 recall on record. Recalls name specific lots - check yours.

What does "pharmacies pay" mean?

It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.

Talk about abacavir 20 mg/ml oral solution

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.